Explore Business Standard
Associate Sponsors
Co-sponsor
The Centre has said there may not be a need to vaccinate the country's entire population against Covid-19 if a critical mass of people are given a shot to break the chain of virus transmission, and made it clear it had never spoken about inoculating everyone. The Centre also asserted that an ''adverse event'' allegedly suffered by a participant in the clinical trial of Oxford-AstraZeneca COVID-19 vaccine by the Serum Institute of India (SII) will not impact in any manner the timeline for its rollout. Also, it said the initial findings of a probe into the event did not necessitate halting of the trials of the vaccine.